Gilead Sciences Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
79.92-1.46 (-1.79%)
As of 11:14 AM EDT. Market open.
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close81.37
Bid79.98 x 400
Ask79.99 x 800
Day's Range79.92 - 81.13
52wk Range76.67 - 111.11
1y Target EstN/A
Market Cap105.46B
P/E Ratio (ttm)7.01
Avg Vol (3m)10,652,700
Dividend & Yield1.88 (2.31%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Market Realist10 minutes ago

    What’s the Upside Potential for Gilead?

    According to a Bloomberg consensus of 28 brokerage firms on September 20, 2016, 60.7% of the firms rated Gilead a “buy,” while 39.3% rated it a “hold.”

  • Barrons.com29 minutes ago

    Gilead Sciences: A 'Slight Uplift' for R&D Strategy?

    Over the weekend, Gilead Sciences (GILD) partner Galapagos (GLPG) announced positive results from a Phase II trial for a Crohn's disease treatment. Leerink's Geoffrey Porges and Bradley Canino consider the implications: Last night, Gilead partner Galapagos announced endoscopic and histopathological results, for FITZROY, their phase 2 trial of JAK1 inhibitor filgotinib in Crohn's disease – with positive trends observed for the treatment arms. With regard to endoscopic data, the percentage of actively treated patients with a Simple Endoscopic Score for Crohn's Disease (SES-CD) improvement of at least 50% was 25% in contrast to the percentage of patients receiving placebo, which was 13.6%.

  • Market Realist1 hour ago

    Gilead’s TAF-Based Regimen Should Drive HIV Franchise Revenue

    With products such as Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla and Truvada, Gilead Sciences (GILD) dominates the HIV market.